151 related articles for article (PubMed ID: 32606967)
1. Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib.
Chen X; Huang Z; Wu W; Xia R
Cancer Manag Res; 2020; 12():4777-4787. PubMed ID: 32606967
[TBL] [Abstract][Full Text] [Related]
2. USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia.
Liao Y; Liu N; Xia X; Guo Z; Li Y; Jiang L; Zhou R; Tang D; Huang H; Liu J
Cell Discov; 2019; 5():24. PubMed ID: 31044085
[TBL] [Abstract][Full Text] [Related]
3. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
[TBL] [Abstract][Full Text] [Related]
4. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis.
Han Y; Ma Z
Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348
[TBL] [Abstract][Full Text] [Related]
5. The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia.
Chen Y; Wang T; Du J; Li Y; Wang X; Zhou Y; Yu X; Fan W; Zhu Q; Tong X; Wang Y
Cell Physiol Biochem; 2018; 47(3):981-993. PubMed ID: 29843123
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
7. Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells.
Chen JY; Wang MC; Hung WC
J Cell Physiol; 2011 Feb; 226(2):407-13. PubMed ID: 20717963
[TBL] [Abstract][Full Text] [Related]
8. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
9. Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.
Liu Y; Shao Z; Liao Y; Xia X; Huang C; He J; Hu T; Yu C; Jiang L; Liu J; Huang H
Eur J Pharmacol; 2020 Sep; 883():173366. PubMed ID: 32679184
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Siah2 Ubiquitin Ligase by Vitamin K3 Attenuates Chronic Myeloid Leukemia Chemo-Resistance in Hypoxic Microenvironment.
Huang J; Lu Z; Xiao Y; He B; Pan C; Zhou X; Xu N; Liu X
Med Sci Monit; 2018 Feb; 24():727-735. PubMed ID: 29400343
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
13. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
Tan Z; Peng A; Xu J; Ouyang M
BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554
[TBL] [Abstract][Full Text] [Related]
14. KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia.
Zhang C; Shen L; Zhu Y; Xu R; Deng Z; Liu X; Ding Y; Wang C; Shi Y; Bei L; Wei D; Thorne RF; Zhang XD; Yu L; Chen S
Theranostics; 2021; 11(6):2691-2705. PubMed ID: 33456567
[No Abstract] [Full Text] [Related]
15. LncRNA OIP5-AS1 Promotes the Autophagy-Related Imatinib Resistance in Chronic Myeloid Leukemia Cells by Regulating miR-30e-5p/ATG12 Axis.
Dai H; Wang J; Huang Z; Zhang H; Wang X; Li Q; Feng W
Technol Cancer Res Treat; 2021; 20():15330338211052150. PubMed ID: 34723728
[No Abstract] [Full Text] [Related]
16. Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway.
Yuan R; Chang J; He J
Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):81-85. PubMed ID: 33040790
[TBL] [Abstract][Full Text] [Related]
17. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
Nie ZY; Yao M; Yang Z; Yang L; Liu XJ; Yu J; Ma Y; Zhang N; Zhang XY; Liu MH; Jiang LL; Luo JM
J Exp Clin Cancer Res; 2020 Jan; 39(1):17. PubMed ID: 31952546
[TBL] [Abstract][Full Text] [Related]
18. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY
Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
[TBL] [Abstract][Full Text] [Related]
19. Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation.
Shen Q; Liu S; Chen Y; Yang L; Chen S; Wu X; Li B; Lu Y; Zhu K; Li Y
J Hematol Oncol; 2013 Sep; 6():64. PubMed ID: 24004697
[TBL] [Abstract][Full Text] [Related]
20. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
